OBJECTIVE: Our goal was to evaluate the existing literature on psychological, social, and behavioral aspects of chronic hepatitis C viral (HCV) infection and antiviral treatment; provide the state of the behavioral science in areas that presently hinder HCV-related health outcomes; and make recommendations for areas in which clinical psychology can make significant contributions. METHOD: The extant literature on HCV and antiviral therapy was reviewed as related to biopsychosocial factors such as mental health, substance/alcohol use, quality of life, coping, stigma, racial disparities, side effects, treatment adherence, integrated care, and psychological interventions. RESULTS: For reasons that have not been well elucidated, individuals infected with HCV experience psychological and somatic problems and report poor health-related quality of life. Preexisting conditions, including poor mental health and alcohol/substance use, can interfere with access to and successful completion of HCV treatment. Perceived stigma is highly prevalent and associated with psychological distress. Racial disparities exist for HCV prevalence, treatment uptake, and treatment success. During HCV treatment, patients experience exacerbation of symptoms, treatment side effects, and poorer quality of life, making it difficult to complete treatment. Despite pharmacological advances in HCV treatment, improvements in clinical and public health outcomes have not been realized. The reasons for this lack of impact are multifactorial, but include suboptimal referral and access to care for many patients, treatment-related side effects, treatment nonadherence, and lack of empirically based approaches. CONCLUSIONS: Biomedical advances in HCV and antiviral treatment have created a fertile field in which psychologists are uniquely positioned to make important contributions to HCV management and treatment.
OBJECTIVE: Our goal was to evaluate the existing literature on psychological, social, and behavioral aspects of chronic hepatitis C viral (HCV) infection and antiviral treatment; provide the state of the behavioral science in areas that presently hinder HCV-related health outcomes; and make recommendations for areas in which clinical psychology can make significant contributions. METHOD: The extant literature on HCV and antiviral therapy was reviewed as related to biopsychosocial factors such as mental health, substance/alcohol use, quality of life, coping, stigma, racial disparities, side effects, treatment adherence, integrated care, and psychological interventions. RESULTS: For reasons that have not been well elucidated, individuals infected with HCV experience psychological and somatic problems and report poor health-related quality of life. Preexisting conditions, including poor mental health and alcohol/substance use, can interfere with access to and successful completion of HCV treatment. Perceived stigma is highly prevalent and associated with psychological distress. Racial disparities exist for HCV prevalence, treatment uptake, and treatment success. During HCV treatment, patients experience exacerbation of symptoms, treatment side effects, and poorer quality of life, making it difficult to complete treatment. Despite pharmacological advances in HCV treatment, improvements in clinical and public health outcomes have not been realized. The reasons for this lack of impact are multifactorial, but include suboptimal referral and access to care for many patients, treatment-related side effects, treatment nonadherence, and lack of empirically based approaches. CONCLUSIONS: Biomedical advances in HCV and antiviral treatment have created a fertile field in which psychologists are uniquely positioned to make important contributions to HCV management and treatment.
Authors: Sascha Russo; Ido P Kema; Elizabeth B Haagsma; Jim C Boon; Pax H B Willemse; Johan A den Boer; Elisabeth G E de Vries; Jakob Korf Journal: Psychosom Med Date: 2005 Sep-Oct Impact factor: 4.312
Authors: Alexander J Thompson; Andrew J Muir; Mark S Sulkowski; Dongliang Ge; Jacques Fellay; Kevin V Shianna; Thomas Urban; Nezam H Afdhal; Ira M Jacobson; Rafael Esteban; Fred Poordad; Eric J Lawitz; Jonathan McCone; Mitchell L Shiffman; Greg W Galler; William M Lee; Robert Reindollar; John W King; Paul Y Kwo; Reem H Ghalib; Bradley Freilich; Lisa M Nyberg; Stefan Zeuzem; Thierry Poynard; David M Vock; Karen S Pieper; Keyur Patel; Hans L Tillmann; Stephanie Noviello; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; David B Goldstein; John G McHutchison Journal: Gastroenterology Date: 2010-04-24 Impact factor: 22.682
Authors: Jason Grebely; Elizabeth Knight; Krista A Genoway; Mark Viljoen; Milan Khara; Doug Elliott; Lesley Gallagher; Michelle Storms; Jesse D Raffa; Stanley DeVlaming; Fiona Duncan; Brian Conway Journal: Eur J Gastroenterol Hepatol Date: 2010-03 Impact factor: 2.566
Authors: Johan Westin; L M Lagging; F Spak; N Aires; E Svensson; M Lindh; A P Dhillon; G Norkrans; R Wejstål Journal: J Viral Hepat Date: 2002-05 Impact factor: 3.728
Authors: Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas Journal: J Community Health Date: 2008-06
Authors: John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir Journal: N Engl J Med Date: 2009-04-30 Impact factor: 91.245
Authors: John G McHutchison; Michael Manns; Keyur Patel; Thierry Poynard; Karen L Lindsay; Christian Trepo; Jules Dienstag; William M Lee; Carmen Mak; Jean-Jacques Garaud; Janice K Albrecht Journal: Gastroenterology Date: 2002-10 Impact factor: 22.682
Authors: Joseph A Boscarino; Mei Lu; Anne C Moorman; Stuart C Gordon; Loralee B Rupp; Philip R Spradling; Eyasu H Teshale; Mark A Schmidt; Vinutha Vijayadeva; Scott D Holmberg Journal: Hepatology Date: 2015-01-30 Impact factor: 17.425
Authors: Lan Dam; Anita Cheng; Phuong Tran; Shirley S Wong; Ronald Hershow; Sheldon Cotler; Scott J Cotler Journal: Can J Gastroenterol Hepatol Date: 2016-12-22
Authors: David A Wohl; Andrew G Allmon; Donna Evon; Christopher Hurt; Sarah Ailleen Reifeis; Harsha Thirumurthy; Becky Straub; Angela Edwards; Katie R Mollan Journal: Open Forum Infect Dis Date: 2017-05-05 Impact factor: 3.835
Authors: Donna M Evon; Paul W Stewart; Jipcy Amador; Marina Serper; Anna S Lok; Richard K Sterling; Souvik Sarkar; Carol E Golin; Bryce B Reeve; David R Nelson; Nancy Reau; Joseph K Lim; K Rajender Reddy; Adrian M Di Bisceglie; Michael W Fried Journal: PLoS One Date: 2018-08-01 Impact factor: 3.240
Authors: Thuc Thi Minh Vu; Thieu Van Le; Anh Kim Dang; Long Hoang Nguyen; Binh Cong Nguyen; Bach Xuan Tran; Carl A Latkin; Cyrus S H Ho; Roger C M Ho Journal: Int J Environ Res Public Health Date: 2019-01-17 Impact factor: 3.390